Vitaminler ve Non Alkolik Yağlı Karaciğer Hastalığı

Yıl 2022, , 383 - 393, 31.05.2022

Aziz Kılınç , Yasemin Akdevelioğlu

https://doi.org/10.46237/amusbfd.1033604

Öz

Artan obezite prevalansına paralel olarak non alkolik yağlı karaciğer hastalığı birçok ülkede en yaygın karaciğer hastalığı haline gelmiştir. Non alkolik yağlı karaciğer hastalığı kardiyovasküler, hepatik, metabolik ve onkolojik sekellerinin yanı sıra karaciğer naklinin önde gelen nedeni haline geldiği için dünya çapında önemli bir morbidite ve mortalite nedenidir. Bu salgın ve sonuçları, dünyanın dört bir yanından uzmanları, hastalığın yönetimi ve tedavisi için etkili stratejiler belirlemeye yönlendirmiştir. Şu anda non alkolik yağlı karaciğer hastalığı için onaylanmış bir ilaç tedavisi yoktur. Bu nedenle diyet ve egzersiz gibi değiştirilebilir risk faktörleri hastalığın yönetimi ve tedavisinde köşe taşı olarak yerini korumaktadır. Vitaminler sağlıklı yaşam için hayati önem taşıyan mikro besin öğeleridir. Bazı çalışmalar yağlı karaciğer hastalığını vitamin eksiklikleri ile ilişkilendirse de bu ilişkilerin altında yatan mekanizma tam olarak aydınlatılamamıştır. Bu nedenle, bu derleme, vitaminlerin non alkolik yağlı karaciğer hastalığı patogenezindeki rolünü tartışmayı ve hastalık yönetiminde potansiyel faydalarını araştırmayı amaçlamaktadır.

Anahtar Kelimeler

Non alkolik yağlı karaciğer hastalığı, Non alkolik yağlı karaciğer hastalığı, Vitaminler, Riboflavin, Askorbik asid

Destekleyen Kurum

Yok

Proje Numarası

-

Teşekkür

-

Vitamins and Non Alcoholic Fatty Liver Disease

Öz

In parallel with the increasing obesity prevalence, non-alcoholic fatty liver disease has become the most common liver disease in many countries. Non-alcoholic fatty liver disease is an important cause of morbidity and mortality worldwide, as it has become the leading cause of liver transplantation, as well as cardiovascular, hepatic, metabolic and oncological sequelae. This epidemic and its consequences have prompted experts from around the world to identify effective strategies for the management and treatment of the disease. There is currently no approved drug therapy for the treatment of non-alcoholic fatty liver disease. Therefore, modifiable risk factors such as diet and exercise remain as cornerstones in the management and treatment of the disease. Vitamins are micronutrients that are vital for a healthy life. Some studies have linked fatty liver disease with vitamin deficiencies. However, the mechanism underlying these relationships has not been fully elucidated. Therefore, this review aims to discuss the role of vitamins in the pathogenesis of non-alcoholic fatty liver disease and explore their potential benefits in disease management.

Anahtar Kelimeler

Non-alcoholic fatty liver disease, Vitamins, Riboflavin, Ascorbic acid

Proje Numarası

-

Kaynakça

• 1. Ullah, R., Rauf, N., Nabi, G., Ullah, H., Shen, Y., Zhou, Y. -D., et al. (2019). Role of nutrition in the pathogenesis and prevention of non-alcoholic fatty liver disease: recent updates. International Journal of Biological Sciences, 15(2), 265-276.
• 2. Yki-Järvinen, H., Luukkonen P.K., Hodson, L., & Moore, J. B. (2021). Dietary carbohydrates and fats in nonalcoholic fatty liver disease. Nature Reviews Gastroenterology & Hepatology, 18, 770-786.
• 3. Kashiwagi, K., Takayama, M., Fukuhara, K., Shimizu-Hirota, R., Chu, P. S., Nakamoto, N., et al. (2020). A significant association of non-obese non-alcoholic fatty liver disease with sarcopenic obesity. Clinical Nutrition ESPEN, 38, 86-93.
• 4. De Chiara, F., Ureta Checcllo, C., & Ramón Azcón, J. (2019). High protein diet and metabolic plasticity in non-alcoholic fatty liver disease: myths and truths. Nutrients, 11, 2985.
• 5. Kalafati, I. P., Borsa, D., Dimitriou, M., Revenas, K., Kokkinos, A., & Dedoussis, G. (2018). Dietary patterns and non-alcoholic fatty liver disease in a Greek case-control study. Nutrition, 61, 105-110.
• 6. Plauth, M., Bernal, W., Dasarathy, S., Merli, M., Plank, L. D., Schütz, T., et al. (2019). ESPEN guideline on clinical nutrition in liver disease. Clinical Nutrition, 38(2), 485-521.
• 7. Xia, Y., Wang, X., Zhang, S., Zhang, Q., Liu, L., Meng, G., et al. (2019). Daily tea drinking is not associated with newly diagnosed non-alcoholic fatty liver disease in Chinese adults: the Tianjin chronic low-grade systemic inflammation and health cohort study. Nutr J, 18 (71), 1-8.
• 8. Chakravarty, M. V., Waddell, T., Banerjee, R., & Guess, N. (2020). Nutrition and nonalcoholic fatty liver disease. Gastroenterology Clinics of North America, 49(1), 63-94.
• 9. Riazi, K., Raman, M., Taylor, L., Swain, M. G., & Shaheen A. A. (2019). Dietary patterns and components in nonalcoholic fatty liver disease (NAFLD): What key messages can health care providers offer? Nutrients, 11(12), 2878.
• 10. Pickett-Blakely, O., Young, K., & Carr, R. (2018). Micronutrients in nonalcoholic fatty liver disease pathogenesis. Cellular and Molecular Gastroenterology and Hepatology, 6(4), 451-462.
• 11. Shiota, G., & Kanki, K. (2013). Retinoids and their target genes in liver functions and diseases. J Gastroenterol Hepatol, 28 (Suppl 1), 33-37.
• 12. Raza, S., Tewari, A., Rajak, S., & Sinha, R. A. (2021). Vitamins and non-alcoholic fatty liver disease: A molecular insight. Liver Research, 5(2), 62-71.
• 13. Abe R. A. M., Masroor, A., Khorochkov, A., Prieto, J., Singh, K. B., Nnadozie, M. C., et al. (2021). The role of vitamins in non-alcoholic fatty liver disease: A systematic review. Cureus, 13(8), e16855-e16855.
• 14. Allam, A. S., Salama, M. M., Nasser, H. M., Kabiel, W. A. Y., & Elsayed, E. H. (2020). Comparison between NAFLD fibrosis score and retinoic acid serum level in NAFLD. Egyptian Liver Journal, 10(2), 1-7.
• 15. Liu, Y., Chen, H., Wang, J., Zhou, W., Sun, R., & Xia, M. (2015). Association of serum retinoic acid with hepatic steatosis and liver injury in nonalcoholic fatty liver disease. Am J Clin Nutr, 102(1), 130-137.
• 16. Wang, X., Chen, X., Zhang, H., Pang, J., Lin, J., Xu, X., et al. (2020). Circulating retinol-binding protein 4 is associated with the development and regression of non-alcoholic fatty liver disease. Diabetes & Metabolism, 46(2), 119-128.
• 17. Coelho, J. M., Cansanção, K., Perez, R. M., Leite, N. C., Padilha, P., Ramalho, A., et al. (2020). Association between serum and dietary antioxidant micronutrients and advanced liver fibrosis in non-alcoholic fatty liver disease: an observational study. PeerJ, 8(2), e9838.
• 18. Lotfi, A., Saneei, P., Hekmatdost, A., Salehisahlabadi, A., Shiranian, A., & Ghiasvand, R. (2019). The relationship between dietary antioxidant intake and physical activity rate with nonalcoholic fatty liver disease (NAFLD): A case-control study. Clinical Nutrition ESPEN, 34, 45-49.
• 19. Gropper, S. A. S., & Smith, J. L. (2013). Advanced nutrition and human metabolism. Sixth edition. Belmont, CA: Wadsworth/Cengage Learning.
• 20. Barchetta, I., Del Ben, M., Angelico, F., Di Martino, M., Fraioli, A., La Torre, G., et al. (2016). No effects of oral vitamin D supplementation on non-alcoholic fatty liver disease in patients with type 2 diabetes: A randomized, double-blind, placebo-controlled trial. BMC Med, 14, 92.
• 21. Wei, Y., Wang, S., Meng, Y., Yu, Q., Wang, Q., Xu, H., et al. (2020). Effects of vitamin D supplementation in patients with nonalcoholic fatty liver disease: A systematic review and meta-analysis. Int J Endocrinol Metab, 18(3), p. e97205.
• 22. Borges-Canha, M., Neves, J. S., Mendonça, F., Silva, M. M., Costa, C., Cabral, P. M., et al. (2021). The impact of vitamin D in non-alcoholic fatty liver disease: A cross-sectional study in patients with morbid obesity. Diabetes Metab Syndr Obes, 14, 487-495.
• 23. Ampong, I., Watkins, A., Gutierrez-Merino, J., Ikwuobe, J., & Griffiths, H. R. (2020). Dietary protein insufficiency: an important consideration in fatty liver disease? Br J Nutr, 123(6), 601-609.
• 24. Perumpail, B. J., Li, A. A., John, N., Sallam, S., Shah, N. D., Kwong, W., et al. (2018). The role of vitamin E in the treatment of NAFLD. Diseases (Basel, Switzerland), 6(4), 86.
• 25. Ivancovsky, W. D., Fliss-Isakov, N., Salomone, F., Webb, M., Shibolet, O., Kariv, R., et al. (2019). Dietary vitamin E and C intake is inversely associated with the severity of nonalcoholic fatty liver disease. Dig Liver Dis, 51(12), 1698-1705.
• 26. Podszun, M. C., Alawad, A. S., Lingala, S., Morris, N., Huang, W. –C. A., Yang, S., et al. (2020). Vitamin E treatment in NAFLD patients demonstrates that oxidative stress drives steatosis through upregulation of de-novo lipogenesis. Redox Biology, 37, 101710.
• 27. Chalasani, N., Younossi, Z., Lavine, J., Charlton, M., Cusi, K., Rinella, M., et al. (2017). The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases. Hepatology (Baltimore, Md.), 67(1), 328-357.
• 28. Federico, A., Dallio, M., Caprio, G. G., Gravina, A. G., Picascia, D., Masarone, M., et al. (2017). Qualitative and quantitative evaluation of dietary ıntake in patients with non-alcoholic steatohepatitis. Nutrients, 9(10), 1074.
• 29. Chen, L., Shu, Y., Liang, X., Chen, E. C., Yee, S. W., Zur, A. A., et al. (2014). OCT1 is a high-capacity thiamine transporter that regulates hepatic steatosis and is a target of metformin. Proc Natl Acad Sci U S A, 111(27): 9983-9988.
• 30. Kalyesubula, M., Mopuri, R., Asiku, J., Rosov, A., Yosefi, S., Edery, N., et al. (2021). High-dose vitamin B1 therapy prevents the development of experimental fatty liver driven by overnutrition. Dis Model Mech, 14(3), dmm048355.
• 31. Vranešić Bender, D., Nutrizio, M., Jošić, M., Ljubas Kelečić, D., Karas, I., Premužić, M., et al. (2017). Nutritional status and nutrition quality in patients with non-alcoholic fatty liver disease. Acta Clin Croat, 56(4), 625-634.
• 32. Ganji, S. H., Kashyap, M. L. & Kamanna, V. S. (2015). Niacin inhibits fat accumulation, oxidative stress, and inflammatory cytokine IL-8 in cultured hepatocytes: Impact on non-alcoholic fatty liver disease. Metabolism, 64(9), 982-990.
• 33. Linder, K., Willmann, C., Kantartzis, K., Machann, J., Schick, F., Graf, M., et al. (2019). Dietary niacin intake predicts the decrease of liver fat content during a lifestyle intervention. Sci Rep, 9(1), 1303.
• 34. Heemskerk, M. M., van den Berg, S. A. A., Pronk, A. C. M., van Klinken, J. –B., Boon, M. R., Havekes, L. M. et al. (2014). Long-term niacin treatment induces insulin resistance and adrenergic responsiveness in adipocytes by adaptive downregulation of phosphodiesterase 3B. American journal of physiology. Endocrinology and metabolism, 306(7), E808-E813.
• 35. Yao, M., Qv, L., Lu, Y., Wang, B., Berglund, B., & Li, L. (2020). An update on the efficacy and functionality of probiotics for the treatment of non-alcoholic fatty liver disease. Engineering, 7(5), 679-686.
• 36. Mazidi, M., Katsiki, N., Mikhailidis, D., & Banach, M. (2019). Adiposity may moderate the link between choline intake and non-alcoholic fatty liver disease. Journal of the American College of Nutrition, 38(7), 633-639.
• 37. Radziejewska, A., Muzsik, A., Milagro, F. I., Martinez, J. A., & Chmurzynska, A. (2020). One-carbon metabolism and nonalcoholic fatty liver disease: The crosstalk between nutrients, microbiota, and genetics. Lifestyle Genom, 13(2), 53-63.
• 38. Guerrerio, A. L., Colvin, R. M., Schwartz, A. K., Molleston, J. P., Murray, K. F., Diehl, A., et al. (2012). Choline intake in a large cohort of patients with nonalcoholic fatty liver disease. Am J Clin Nutr, 95(4), 892-900.
• 39. Kessoku, T., Kobayashi, T., Tanaka, K., Yamamoto, A., Takahashi, K., Iwaki, M., et al. (2021). The role of leaky gut in nonalcoholic fatty liver disease: A novel therapeutic target. International Journal of Molecular Sciences, 22(15), 8161.
• 40. Ferolla, S. M., Ferrari, T. C. A., Lima, M. L. P., Reis, T. O., Tavares, W. C., Couto, O. F. M., et al. (2013). Dietary patterns in Brazilian patients with nonalcoholic fatty liver disease: a cross-sectional study. Clinics (Sao Paulo, Brazil), 68(1),11-17.
• 41. Kobayashi, T., Kessoku, T., Ozaki, A., Iwaki, M., Honda, Y., Ogawa, Y., et al. (2021). Vitamin B6 efficacy in the treatment of nonalcoholic fatty liver disease: an open-label, single-arm, single-center trial. Journal of Clinical Biochemistry and Nutrition, 68(2), 181-186.
• 42. Ferro, Y., Carè, I., Mazza, E., Provenzano, F., Colica, C., Torti, C., et al. (2017). Protein and vitamin B6 intake are associated with liver steatosis assessed by transient elastography, especially in obese individuals. Clin Mol Hepatol, 23(3), 249-259.
• 43. Kim, M.-Y., & Choi, S.-W. (2021). Can walnut serve as a magic bullet for the management of non-alcoholic fatty liver disease? Applied Sciences, 11, 218.
• 44. Vahedi, H., Bavafaetousi, N, Zolfaghari, P., Yarmohammadi, M., & Sohrabi, M. B. (2020). Association between serum folate levels and fatty liver disease. Clinical Nutrition Experimental, 29, 30-35.
• 45. Mahamid, M., Mahroum, N., Bragazzi, N. L., Shaalata, K., Yavne, Y., Adawi, M., et al. (2018). Folate and B12 levels correlate with histological severity in NASH patients. Nutrients, 10(4), 440.
• 46. Xin, F. Z., Zhao, Z. H., Zhang, R. N., Pan, Q., Gong, Z. Z., Sun, C., et al. (2020). Folic acid attenuates high-fat diet-induced steatohepatitis via deacetylase SIRT1-dependent restoration of PPARα. World J Gastroenterol, 26(18), 2203-2220.
• 47. Moretti, R., Caruso, P., & Gazzin, S. (2019). Non-alcoholic fatty liver disease and neurological defects. Ann Hepatol, 18(4), 563-570.
• 48. Li, J., Cordero, P., Nguyen, V., & Oben, J. A. (2016). The role of vitamins in the pathogenesis of non-alcoholic fatty liver disease. Integrative medicine insights, 11, 19-25.
• 49. Sharma, C. & Badyal, A. (2021). Association between vitamin B12 and non-alcoholic fatty liver disease: a case control study in Katra Jammu. International Journal of Basic & Clinical Pharmacology, 10(6), 726.
• 50. Polyzos, S. A., Kountouras, J., Patsiaouro, K., Katsiki, E., Zafeiriadou, E., Deretzi, G., et al. (2012). Serum homocysteine levels in patients with nonalcoholic fatty liver disease. Ann Hepatol, 11(1), 68-76.
• 51. Longo, M., Meroni, M., Paolini, E., Macchi, C., & Dongiovanni, P. (2021). Mitochondrial dynamics and nonalcoholic fatty liver disease (NAFLD): new perspectives for a fairy-tale ending? Metabolism, 117, 154708.
• 52. Costa, D. S., Guahnon, M. P., Seganfredo, F. B., Pinto, L. P, Tovo, C. V., & Fernandes, S. A. (2021). Vitamin B12 and homocysteine levels in patients with NAFLD: a systematic review and meta-analysis. Arq Gastroenterol, 58(2), 234-239.
• 53. Wei, J., Lei, G. H., Fu, L., Zeng, C., Yang, T., & Peng, S. F. (2016). Association between dietary vitamin C intake and non-alcoholic fatty liver disease: a cross-sectional study among middle-aged and older adults. PLoS One, 11(1), e0147985.
• 54. He, Z., Li, X., Yang, H., Wu, P., Wang, S., Cao, D., et al. (2021). Effects of oral vitamin C supplementation on liver health and associated parameters in patients with non-alcoholic fatty liver disease: a randomized clinical trial. Front Nutr, 8, 745609.
• 55. Vahid, F., Hekmatdoost, A., Mirmajidi, S., Doaei, S., Rahmani, D., & Faghfoori, Z. (2019). Association between index of nutritional quality and nonalcoholic fatty liver disease: the role of vitamin D and B group. The American Journal of the Medical Sciences, 358(3), 212-218.